#1COPYRIGHT © ABCELLERA Q3 2021 BUSINESS UPDATE NOV 9, 2021 AbCellera#2Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 2 DISCLAIMER This entation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe,” “estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3STRONG 17 GROWTH OF CORE BUSINESS Q3 2021. BUSINESS UPDATE SUMMARY. NEW programs under contract 9 NEW programs started 1 MOLECULE entered clinical testing 155 cumulative programs under contract $754M in cash, cash equivalents & marketable securities $44M in accounts & accrued receivable#4100+ DISCOVERY PROGRAMS ANNUALLY DOZENS OF IND FILINGS IN HALF THE TIME OUR VISION. AbCellera Development Antibody Discovery AbCellera Tech Stack Preclinical Expansion into GMP / CMC Manufacturing THE ANCE 6 Partner Development Phase 1, 2, 3, Approval#5Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 5 155 PROGRAMS UNDER CONTRACT 131 WITH DOWNSTREAM PARTICIPATION | '||| DEAL STRUCTURES royalties & milestones equity / equity-like option to Invest INDICATIONS INCLUDE oncology neurodegeneration pain allergic inflammation ophthalmology infectious disease autoimmune diseases women's health cardiovascular#6Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 6 UNLOCKING INNOVATION FOR DRUG DEVELOPERS OF ALL SIZES Next-Gen Modalities Y IgGs, IgMs, IgAs single domain CAR-T Cell therapies Y Y bispecific antibodies radioisotope conjugates CNS-delivered antibodies moderna REGENERON QEQ Pfizer BILL MELINDA GATES foundation Ablynx A SANOT COMPANY Invetx MERCK Lilly gsk NOVARTIS igm DARPA EMPIRICO Autolus TACHYON GILEAD EVEREST MEDICINES SANOFI KODIAK DENALI angios Lyell teva#7Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 7 2 NEW PARTNERSHIPS THAT OPEN NEW MARKETS & PIONEER NEW MODALITIES EVEREST MEDICINES 10 targets multi-year Qoncology + multiple indications moderna 6 targets multi-year multiple indications#8Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 EXPAND CAPABILITIES AGAINST TARGETS DIFFICULT-TO-DRUG WITH ACQUISITION OF TETRAGENETICS GPCR and ion channel proteins are high value, difficult-to-drug targets. Integrating TetraGenetics into our tech stack provides an optimized source of proteins for our antibody discovery efforts and solves a key challenge in pursuing these highly sought-after, but difficult-to-drug targets. 000f M Hi!#9Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 CREATING VALUE WITH BISPECIFICS OrthoMab™ bispecific engineering platform, coupled with our discovery engine, provides partners with a rapid and complete solution. for generating tailored, stable, and developable bispecific antibodies. H#10Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 EMPOWER NEXT-GEN ANTI-CD3 ANTIBODIES FOR ONCOLOGY Large and growing market opportunity in the use of bispecifics specifically for T cell redirection in oncology through CD3 receptor engagement on T cells. O CD3+ T Cell O Target Cell#11Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 11 CONGRATULATIONS TO INVETX FOR ADVANCING IVX-01 INTO CLINICAL TESTING IVX-01 is an antibody treatment for an undisclosed chronic indication in dogs. mm Invetx TM#12Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 12 EXPAND CAPABILITIES. BUILD CAPACITY. EXTEND COMMERCIAL REACH. 1 Increase programs under contract 2 Forward integration of our tech stack 3 Scale teams and facilities 4 Further technology differentiation 5 Improve speed, increase predictive power#13o COPYRIGHT © ABCELLERA Q3 2021 FINANCIALS UPDATE#14FINANCIALS Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 14 Partnership business on track for strongest year on all key metrics. # of Discovery Partners 35 30 25 20 15 10 5 O 35 2015 2016 2017 2018 2019 2020 Q3 2021 Cumulative # of Programs Under Contract 160 140 120 100 80 60 40 20 O WITHOUT downstream participation + WITH downstream participation 155 2015 2016 2017 2018 2019 2020 Q3 2021 Cumulative # of Program Starts 70 60 50 40 30 20 10 O 69 2015 2016 2017 2018 2019 2020 Q3 2021 Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results.#15FINANCIALS Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 15 Five molecules in the clinic, over a dozen in preclinical development. MOLECULE bamlanivimab (LY-CoV555) bebetelovimab (LY-CoV1404) NBL-012 NBL-015 IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Phase II Phase I IND approved Clinical field study PARTNER Lilly Lilly NovaRock BIOTHERAPEUTICS NovaRock BOTHERAPEUTICS Invetx THERAPEUTIC AREA COVID-19 ● COVID-19 • dermatology gastrointestinal disease • immunology oncology animal health PROGRAM TYPE AbCellera Discovery Partnership Trianni License AbCellera Discovery Partnership#16FINANCIALS Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 16 $5.5M revenue reflects robust discovery partnership activity. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $9.4M $5.0M $4.4M Q3 2020 $5.5M $0.2M $0.2M $5.1M Q3 2021#17FINANCIALS Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 17 Operating expenses continue to reflect strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT r I I I I $7.5M +$10.0M Q3 2020 -1 I $17.5M Q3 2021 SALES & MARKETING $0.6M Q3 2020 +$0.6M 1 $1.2M Q3 2021 GENERAL & ADMIN $3.0M Q3 2020 +$8.3M -1 I $11.3M Q3 2021#18FINANCIALS Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 18 Net loss of $21.4M: Equivalent to ($0.08) per share (basic & diluted). Earnings / Loss USD Q3 -$2.7M 2020 NET EARNINGS (LOSS) -$21.4M 2021 First 9 Months $1.9M 2020 $93.5M 2021 EARNINGS (LOSS) PER SHARE: BASIC & DILUTED Q3 -$0.02 2020 -$0.08 2021 First 9 Months $0.01 2020 $0.34 BASIC $0.29 DILUTED 2021#19FINANCIALS Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 19 Total short-term liquidity nearly $800 million. Cash Flows USD $594.1M CASH & EQUIVALENTS & MARKETABLE SECURITIES 2020 Y/E $261.3M OPERATIONS $49.0M PPGE ($95.3M) INVESTMENT¹ 1. excluding marketable securities ($5.7M) FINANCING ($0.9M) FX Additionally, $44M AR + accrued AR balance at quarter end $753.5M CASH & EQUIVALENTS & MARKETABLE SECURITIES SEP 30#2020 COPYRIGHT © ABCELLERA Q3 2021 BUSINESS UPDATE YOU THANK